Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Gilead Sciences (NQ:GILD)

126.64 -0.55 (-0.43%)
Streaming Delayed Price Updated: 12:55 PM EST, Nov 19, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Gilead Sciences

< Previous 1 2
...
19 20 21 22 23 24 25 26 27
...
68 69 Next >
News headline image
Encouraging New Data Presented on Kite’s Yescarta® for Relapsed/Refractory Central Nervous System Lymphoma
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Gilead and Arcus Announce Etrumadenant Plus Zimberelimab Regimen Significantly Reduced the Risk of Death in Third-line Metastatic Colorectal Cancer
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Gilead and Arcus Announce Anti-TIGIT Domvanalimab Plus Zimberelimab and Chemotherapy Exceeded One Year of Median Progression-Free Survival as a First-Line Treatment for Upper GI Cancers
From Gilead Sciences, Inc.
Via Business Wire
News headline image
$100 Invested In This Stock 20 Years Ago Would Be Worth $800 Today ↗
 
Via Benzinga
News headline image
Market Whales and Their Recent Bets on GILD Options ↗
 
Via Benzinga
News headline image
Gilead's Trodelvy Fails To Hit Primary Goal In Late-Stage Study With Most Common Type Of Bladder Cancer ↗
Gilead Sciences' announced topline results from the Phase 3 TROPiCS-04 study on Trodelvy for metastatic urothelial cancer. The study did not meet the primary endpoint of overall survival but showed... 
Via Benzinga
News headline image
EVOKE-01 Study Results in Metastatic NSCLC to Be Presented at an Oral Session at ASCO 2024
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Gilead Provides Update on Phase 3 TROPiCS-04 Study
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Is Nvidia Worth 35x Times Sales, History Says No ↗
You wouldn’t be able to tell just by looking at the S&P 500 daily change of +0.02%, but Tuesday was a pretty negative day, with the S&P 500 equal weight RSP ETF finishing down by almost 70 bps. 
Via Talk Markets
Topics ETFs Stocks
News headline image
Decoding Gilead Sciences's Options Activity: What's the Big Picture? ↗
 
Via Benzinga
News headline image
Why NASDAQ:GILD qualifies as a good dividend investing stock. ↗
Why GILEAD SCIENCES INC (NASDAQ:GILD) is a Top Pick for Dividend Investors. 
Via Chartmill
News headline image
2 Beaten-Down Dividend Stocks to Buy and Hold For 10 Years ↗
These companies have grown their dividends despite some troubles. 
Via The Motley Fool
News headline image
7 Biotech Stocks to Put on Your Breakthrough Radar ↗
Although biotech stocks can present volatility risks due to its feast-or-famine nature, their narrative offers permanent relevance. 
Via InvestorPlace
News headline image
3 Biotech Stocks to Buy Now: May 2024 ↗
As the biotech industry continues to rise in market prominence, investors should start considering what the best biotech stocks to buy are. 
Via InvestorPlace
News headline image
Gilead to Present Latest Research Across Key Liver Disease Indications at the European Association for the Study of the Liver Congress 2024
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Large Cap Biopharmaceuticals Performance ↗
The biotech sector remains a laggard YTD as can be seen by the IBB​​​​​​​. 
Via Talk Markets
News headline image
$1000 Invested In This Stock 20 Years Ago Would Be Worth $9,300 Today ↗
 
Via Benzinga
News headline image
Gilead Sciences Unusual Options Activity For May 06 ↗
 
Via Benzinga
News headline image
How Is The Market Feeling About Gilead Sciences? ↗
 
Via Benzinga
News headline image
Gilead's Recently Acquired Liver Disease Candidate Shows Improvements In Disease Progression And Associated Itch ↗
Gilead Sciences reports interim results from the ASSURE study of seladelpar in primary biliary cholangitis, showing significant improvements in cholestasis markers and pruritus. 
Via Benzinga
News headline image
The P3 App: Empowering and Elevating Underprivileged Youth from Socioeconomically Disadvantaged Areas Through Innovative Mentorship
CHICAGO - May 18, 2024 - PRLog -- The Pulse of Perseverance alongside Gilead is proud to announce the launch of the P3 mobile app, a pioneering platform unveiled at our signature benefit event on May... 
Via PRLog
News headline image
Investigational Seladelpar Demonstrates Significant Improvements in Liver Disease Progression and Reduced Itching in Primary Biliary Cholangitis
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Penny Stock Sleepers: 7 Under-the-Radar Gems Ready to Launch ↗
Penny stocks to buy understandably offers many enticing attributes, not least of which is the potential for tremendous returns. 
Via InvestorPlace
News headline image
Kite Data at EHA 2024 Demonstrate Positive Patient Outcomes and Advances in Delivery of CAR T-cell Therapy
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Kite and Arcellx Continue Momentum with Advances in Anito-Cel Multiple Myeloma Program
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Biotech Breakthroughs: 3 Stocks on the Verge of Revolutionizing Medicine ↗
These biotech breakthrough stocks give investors a glimpse into medicine's future -- and massive moneymaking opportunities to boot. 
Via InvestorPlace
News headline image
Gilead and Kite Oncology to Highlight Broad and Diverse Oncology Portfolio at ASCO 2024
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Bargain Hunting: 7 Stocks Near 52-Week Lows to Buy Before the Bounce Back ↗
If you want your shot at significant upside, speculate on these stocks near 52-week lows that can prove the critics wrong. 
Via InvestorPlace
News headline image
Shhh! 3 Secret Biotech Stocks Flying Below Wall Street’s Radar ↗
These biotech stocks seem to be rich with intriguing growth plays going for very reasonable multiples this May. 
Via InvestorPlace
News headline image
Gilead Sciences to Present at Upcoming Investor Conferences
From Gilead Sciences, Inc.
Via Business Wire
< Previous 1 2
...
19 20 21 22 23 24 25 26 27
...
68 69 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.